Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Redhill Biophrma ADR (RDHL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 111,455
  • Shares Outstanding, K 21,270
  • Annual Sales, $ 100 K
  • Annual Income, $ -29,370 K
  • 36-Month Beta 0.40
  • Price/Sales 53.07
  • Price/Cash Flow N/A
  • Price/Book 2.62

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.70 +12.87%
on 12/26/17
5.55 -4.41%
on 01/04/18
+0.46 (+9.61%)
since 12/22/17
3-Month
4.30 +23.37%
on 12/06/17
9.33 -43.14%
on 10/23/17
-3.95 (-42.65%)
since 10/20/17
52-Week
4.30 +23.37%
on 12/06/17
11.25 -52.84%
on 10/02/17
-4.92 (-48.09%)
since 01/20/17

Most Recent Stories

More News
RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam(R) to Savings Program for Uninsured or Underinsured Patients

RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization...

RDHL : 5.30 (+1.15%)
ESRX : 81.08 (+1.07%)
RedHill Biopharma Announces Final Results from Phase II Study with BEKINDA(R) for IBS-D

RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization...

RDHL : 5.30 (+1.15%)
IntelGenx to Regain Exclusive Worldwide Rights to Develop and Commercialize RIZAPORT(R)

FDA Requests More Information Before Full Review of RIZAPORT(R) NDA Resubmission

RDHL : 5.30 (+1.15%)
IGXT : 0.7800 (+1.30%)
IGX.VN : 0.950 (-1.04%)
RedHill Biopharma Provides 2017 Year-End Business Update

RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization...

RDHL : 5.30 (+1.15%)
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares

RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization...

RDHL : 5.30 (+1.15%)
RedHill Biopharma Reports 2017 Third Quarter Financial Results

- RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017

RDHL : 5.30 (+1.15%)
RedHill Biopharma Reports 2017 Third Quarter Financial Results

-- RedHill maintains a debt-free balance sheet with $39.6 million in cash at the end of the third quarter of 2017

RDHL : 5.30 (+1.15%)
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

-- Top-line results are expected to be announced in mid-2018

RDHL : 5.30 (+1.15%)
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn's Disease

- Top-line results are expected to be announced in mid-2018

RDHL : 5.30 (+1.15%)
RedHill Biopharma Prices Public Offering of its American Depositary Shares

TEL-AVIV, Israel and RALEIGH, N.C., Nov. 08, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company...

RDHL : 5.30 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More

Business Summary

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers...

See More

Key Turning Points

2nd Resistance Point 5.35
1st Resistance Point 5.30
Last Price 5.30
1st Support Level 5.18
2nd Support Level 5.11

See More

52-Week High 11.25
Fibonacci 61.8% 8.60
Fibonacci 50% 7.78
Fibonacci 38.2% 6.95
Last Price 5.30
52-Week Low 4.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.